GlassScriptPhysician profile
Qing Yu
NPI 1871755322
$1,192.15
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $214 · 2021: $84.91 · 2022: $155 · 2023: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.89 | 2019-2023 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.78 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $81.40 | 2019-2022 | |
| Braintree Laboratories, INC. | $61.38 | 2019-2023 | Sutab |
| Ferring Pharmaceuticals INC. | $58.46 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $45.58 | 2022 | |
| Shionogi INC | $40.98 | 2019 | |
| Genzyme Corporation | $29.36 | 2022 | |
| Gilead Sciences, INC. | $20.40 | 2019 | |
| Daiichi Sankyo INC. | $20.29 | 2019 | |
| Boston Scientific Corporation | $19.04 | 2020 | |
| Romark Laboratories, Lc | $18.21 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.